Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can we predict lung transplant outcomes? new study seeks answers

NCT ID NCT07356752

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 4,200 lung transplant recipients in France to understand why some people develop serious complications like chronic lung allograft dysfunction (CLAD). Researchers will collect routine health data, lung function tests, and blood samples to build a model that predicts how well a transplanted lung will work over time. The goal is to identify early warning signs so doctors can act sooner and personalize care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better tools for doctors to predict and catch lung transplant problems early, potentially improving long-term survival.
What could go wrong
This is an observational study, not a treatment trial. It may not directly change patient care, and the prediction models might not work as well in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 4,200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients aged 15 and over transplanted (first or re transplantation, single, bilateral or combined) between 01/01/2009 and the date of the first prospective inclusion, benefiting from regular monitoring in one of the participating centers 2. Or Newly transplanted patient single, bilateral LTx, combined LTx) aged of 15 or more at the moment of transplantation, in one of the participating centers between the date of the first prospective inclusion during three years 3. Patients understanding the French language 4. Having signed an informed consent form for this study\*, and for patients aged 15 to 18 that the holder(s) of parental authority has signed the informed consent 5. Being covered by a national health insurance \* Already transplanted patient deceased before the beginning of the study: only clinical data (including biological samples clinically indicated likely to be reused, like serum of transbronchial biopsy (tbb)) will be included under condition of tracing any refusal, reluctance, reservations to the use of data, in patient files, by text analysis in all available digital documents. This approach allows both an exhaustive analysis in a timely, rapid way, that human reading would not allow. In case of mention of refusal, reluctance, reservations, the patient's data will not be collected. Exclusion Criteria: 1. Hemoglobin levels inferior than or equal to 8g/dl 2. Patients not understanding the French language 3. Don't being covered by a national health insurance 4. Being under guardianship or curatorship 5. Pregnant women\* \* Candidate for LTx are not allowed for pregnancy. During the follow up, pregnancies are permitted subject to medical approval of the project and close monitoring. It was decided that during pregnancy the participation for biocollection, would be suspended temporally. Realistically 1/ in the former situation patient candidate for Lung transplantation are not pregnant, 2/ in contrast long after transplantation, medically supervised pregnancy could occur. In that case, research sampling might be suspended temporarily.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lung allograft dysfunction (CLAD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • APHP - site de Bichat

    Paris, Paris 18, 75018, France

  • APHP - site de Cochin

    Paris, Paris 14, 75014, France

  • CHU Bordeaux & INSERM U1045

    Talence, Talence, 33404, France

  • CHU LYON

    Lyon, 69007, France

  • CHU Nantes Hôpital Maison Blanche

    Nantes, 44000, France

  • CHU Strasbourg

    Strasbourg, Strasbourg, 67084, France

  • CML La Fondation Hôpital Saint-Joseph

    Le Plessis-Robinson, 92350, France

  • Chu Grenoble

    Grenoble, 38700, France

  • Hôpital Foch

    Suresnes, 92150, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.